• Home

  • Documents

  • Conflict of Interest Declaration JKJ has financial interests in Editas Medicine, Hera Testing...

If you can't read please download the document

Conflict of Interest Declaration JKJ has financial interests in Editas Medicine, Hera Testing Laboratories, Poseida Therapeutics, and Transposagen Biopharmaceuticals

Embed Size (px)

Ex vivo applications of Cas12a - Editas Medicine€¦ · Adapted from Canver and Orkin, Blood, 2016 Globin switch Onset of SCD Symptoms d g b e a 0 25 50 75 100 0 3 6 9 12 15 18 hesis

Ex vivo applications of Cas12a - Editas Medicine€¦ · Adapted from Canver and Orkin, Blood, 2016 Globin switch Onset of SCD Symptoms d g b e a 0 25 50 75 100 0 3 6 9 12 15 18 hesis

Documents
in this section · Ventures was the only participant in the deal.) Editas was launched in November 2013 with $43 million in financing from Flagship Ventures, Polaris Partners and

in this section · Ventures was the only participant in the deal.) Editas was launched in November 2013 with $43 million in financing from Flagship Ventures, Polaris Partners and

Documents
Poseida Español - Libreria DespertarEspañol - Análisis de 'La Atlántida y La Lemuria según Edgar Cayce' - Los Continentes Perdidos a la Luz de los Descubrimientos Modernos - Ancient

Poseida Español - Libreria DespertarEspañol - Análisis de 'La Atlántida y La Lemuria según Edgar Cayce' - Los Continentes Perdidos a la Luz de los Descubrimientos Modernos - Ancient

Documents
Therapeutic Correction of an LCA- Causing Splice Defect in the … · 2020-05-14 · © 2017 Editas Medicine 4 Targeted Deletion in Patient Fibroblasts **** P < 0.0001 *** P < 0.001

Therapeutic Correction of an LCA- Causing Splice Defect in the … · 2020-05-14 · © 2017 Editas Medicine 4 Targeted Deletion in Patient Fibroblasts **** P < 0.0001 *** P < 0.001

Documents
Biography of moderators and speakers - OECD. · PDF fileBiography of moderators and speakers ... in startups Simbol Materials and Editas, and as a ... Social and Governance

Biography of moderators and speakers - OECD. · PDF fileBiography of moderators and speakers ... in startups Simbol Materials and Editas, and as a ... Social and Governance

Documents
Envisioning a Gene Editing Approach to Treat Inherited ... › wp-content › uploads › ...Leber Congenital Amaurosis LCA10 caused by mutations in the CEP290 gene © 2016 Editas

Envisioning a Gene Editing Approach to Treat Inherited ... › wp-content › uploads › ...Leber Congenital Amaurosis LCA10 caused by mutations in the CEP290 gene © 2016 Editas

Documents
EDIT-301: AN AUTOLOGOUS CELL THERAPY TO ......editasmedicine.com © 2020 Editas Medicine 1 EDIT-301: AN AUTOLOGOUS CELL THERAPY TO PROMOTE FETAL HEMOGLOBIN EXPRESSION FOR THE POTENTIAL

EDIT-301: AN AUTOLOGOUS CELL THERAPY TO ......editasmedicine.com © 2020 Editas Medicine 1 EDIT-301: AN AUTOLOGOUS CELL THERAPY TO PROMOTE FETAL HEMOGLOBIN EXPRESSION FOR THE POTENTIAL

Documents
#V.2 Poseida

#V.2 Poseida

Documents
Editas Medicine, Inc., Cambridge MA 02142€¦ · of genome editing informs the design of an optimal composition of RNPs for cationic lipid mediated direct delivery. Biophysical Characterization

Editas Medicine, Inc., Cambridge MA 02142€¦ · of genome editing informs the design of an optimal composition of RNPs for cationic lipid mediated direct delivery. Biophysical Characterization

Documents
Editas Medicine Campaign Project Paper

Editas Medicine Campaign Project Paper

Documents
I3connect.com #cleantechEUROPEevents.cleantech.com/wp-content/uploads/2016/04/... · 2/2/2016 2/22/2016 3/13/2016 4/2/2016 Cellectis Sangamo Editas ... $0.5bn Share price, IPO date

I3connect.com #cleantechEUROPEevents.cleantech.com/wp-content/uploads/2016/04/... · 2/2/2016 2/22/2016 3/13/2016 4/2/2016 Cellectis Sangamo Editas ... $0.5bn Share price, IPO date

Documents
Genome Editing Applications - GIIEventwith the development of delivery solutions for therapeutic applications. David Bumcrot, Ph.D., Senior Director, Molecular & Cell Biology, Editas

Genome Editing Applications - GIIEventwith the development of delivery solutions for therapeutic applications. David Bumcrot, Ph.D., Senior Director, Molecular & Cell Biology, Editas

Documents
Transposagen Genome Engineering Brochure 2014

Transposagen Genome Engineering Brochure 2014

Documents
2015 Industry Snapshot - MassBiofiles.massbio.org/file/Industry-Snapshot-UPDATED-Jan-2016.pdf · Editas Medicine 120.0 Series B Gritstone Oncology 102.0 Series A Syndax Pharmaceuticals

2015 Industry Snapshot - MassBiofiles.massbio.org/file/Industry-Snapshot-UPDATED-Jan-2016.pdf · Editas Medicine 120.0 Series B Gritstone Oncology 102.0 Series A Syndax Pharmaceuticals

Documents
Transposagen Q3 2012 Overview

Transposagen Q3 2012 Overview

Documents
Editas Medicine

Editas Medicine

Documents
Precision Toxicology™ & Efficacy Humanized Liver Mice · Marketing, and Business Development Divisions at Transposagen. Experience in product development, licensing, technology

Precision Toxicology™ & Efficacy Humanized Liver Mice · Marketing, and Business Development Divisions at Transposagen. Experience in product development, licensing, technology

Documents
Fernandez-TIDES-2017 Final for pdf - Editas Medicine · 0.001 0.0742 0.0772 0.016 0.0849 0.2282 0.0221 0.0382 5e−04 0.0058 7e−04 0.0037 2e−04 9e−04 2e−04 2e−04 2e−04

Fernandez-TIDES-2017 Final for pdf - Editas Medicine · 0.001 0.0742 0.0772 0.016 0.0849 0.2282 0.0221 0.0382 5e−04 0.0058 7e−04 0.0037 2e−04 9e−04 2e−04 2e−04 2e−04

Documents
New biologiaytiza.files.wordpress.com  · Web view2020. 6. 16. · El examen está pensado para contestarlo editando con Word con letra Calibri (cuerpo) tamaño 11 o menor. Si editas

New biologiaytiza.files.wordpress.com  · Web view2020. 6. 16. · El examen está pensado para contestarlo editando con Word con letra Calibri (cuerpo) tamaño 11 o menor. Si editas

Documents
Editas Medicine Corporate Presentation

Editas Medicine Corporate Presentation

Documents
Empowering effective cell engineering for a healthier world · – Five new clinical/commercial licences signed in 2019, including with industry leaders Kite (a Gilead Company), Editas

Empowering effective cell engineering for a healthier world · – Five new clinical/commercial licences signed in 2019, including with industry leaders Kite (a Gilead Company), Editas

Documents
BIOTECHNOLOGY, GENOMIC ADVANCEMENTS, AND DNA …€¦ · CAREDX INC 3.4% TWIST BIOSCIENCE CORP. 3.2% EDITAS MEDICINE INC 3.1% WHY INVEST IN EAGB? 1 EXPOSURE TO INNOVATION Aims for

BIOTECHNOLOGY, GENOMIC ADVANCEMENTS, AND DNA …€¦ · CAREDX INC 3.4% TWIST BIOSCIENCE CORP. 3.2% EDITAS MEDICINE INC 3.1% WHY INVEST IN EAGB? 1 EXPOSURE TO INNOVATION Aims for

Documents
Poseida (Spanish Edition) - Swann, Lisa.pdf

Poseida (Spanish Edition) - Swann, Lisa.pdf

Documents
Highly Efficient Multi-Gene Knockout and Transgene Knock ... · © 2020 Editas Medicine 2 Disclosure John Zuris is an employee and shareholder at Editas Medicine

Highly Efficient Multi-Gene Knockout and Transgene Knock ... · © 2020 Editas Medicine 2 Disclosure John Zuris is an employee and shareholder at Editas Medicine

Documents